All the patients enrolled in our study satisfied the WHO criteria, although some mutation-negative patients were borderline between WM and other B-lymphoproliferative disorders or between IgM multiple myeloma and diffuse large B cell lymphoma. The gene discussed is CD40LG; the disease is plasma cell myeloma.